BDC-3042

News alerts, weekly reports and conference planners

Company:

Bolt Biotherapeutics

Drug class:

Dectin-2 agonist

‹

›

3ms

BBI-20233042: Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies (clinicaltrials.gov)

P1, N=17, Terminated, Bolt Biotherapeutics, Inc. | N=147 --> 17 | Trial completion date: Mar 2028 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Aug 2025; Sponsor decision

3 months ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date • First-in-human

Libtayo (cemiplimab-rwlc) • BDC-3042

9ms

BBI-20233042: Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies (clinicaltrials.gov)

P1, N=147, Active, not recruiting, Bolt Biotherapeutics, Inc. | Phase classification: P1/2 --> P1

9 months ago

Phase classification

Libtayo (cemiplimab-rwlc) • BDC-3042

12ms

BBI-20233042: Study of BDC-3042 As Single Agent and in Combination with Cemiplimab in Patients with Advanced Malignancies (clinicaltrials.gov)

P1/2, N=147, Active, not recruiting, Bolt Biotherapeutics, Inc. | Recruiting --> Active, not recruiting

12 months ago

Enrollment closed

Libtayo (cemiplimab-rwlc) • BDC-3042

almost3years

Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042 (AACR 2023)

Systemically administered BDC-3042 mediates anti-tumor efficacy as a monotherapy, and combination with checkpoint blockade therapy enhances anti-tumor efficacy. The data presented demonstrate the therapeutic potential of targeting Dectin-2 expressed by TAMs with the agonistic antibody BDC-3042 as a novel pan-cancer approach for myeloid cell-directed tumor immunotherapy.

almost 3 years ago

IO biomarker

CD8 (cluster of differentiation 8)

BDC-3042